# Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)

> **NCT02579759** · PHASE3 · COMPLETED · sponsor: **Pharnext S.C.A.** · enrollment: 323 (actual)

## Conditions studied

- Charcot-Marie-Tooth Disease Type 1A

## Interventions

- **DRUG:** PXT3003 dose 1
- **DRUG:** PXT3003 dose 2
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02579759
- **Lead sponsor:** Pharnext S.C.A.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2018-03
- **Final completion:** 2018-08
- **Target enrollment:** 323 (ACTUAL)
- **Last updated:** 2020-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02579759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02579759, "Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02579759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*